Page 204 - EJMO-9-3

Eurasian Journal of
Medicine and Oncology Medication therapy based on HbA1c

risk prediction in patients with type 2 diabetes with and price target analysis. Lancet Diabetes Endocrinol.
metabolomics. Cardiovasc Diabetol. 2025;24:581. 2021;9(12):825-836.
doi: 10.1186/s12933-025-02581-3 doi: 10.1016/S2213-8587(21)00240-0
19. Miller V, Micha R, Choi E, Karageorgou D, Webb P, 23. Nelson AJ, Ardissino M, Haynes K, et al. Gaps in evidence-
Mozaffarian D. Evaluation of the quality of evidence of based therapy use in insured patients in the United States with
the association of foods and nutrients with cardiovascular type 2 diabetes mellitus and atherosclerotic cardiovascular
disease and diabetes: A systematic review. JAMA Network disease. J Am Heart Assoc. 2021;10(2):e016835.
Open. 2025;8(3):e2788634. doi: 10.1161/jaha.120.016835
doi: 10.1001/jamanetworkopen.2025.2788634. 24. Wilson LM, Herzig SJ, Marcantonio ER, et al. Management
20. Zhao C, Lin M, Yang Y, Yang H, Gao Z, Yan Z, et al. of diabetes and hyperglycemia in the hospital: A systematic
Association between dietary inflammatory index and review of clinical practice guidelines. Diabetes Care.
cardiovascular-kidney-metabolic syndrome risk: A cross- 2025;48(4):655-664.
sectional study. Nutr J. 2025;24:1127. doi: 10.2337/dc24-2510
doi: 10.1186/s12937-025-01127-3 25. Ikramov A, Mukhtarova S, Trigulova R, Alimova D,
21. Gupta A, Shah K, Gupta V. Interconnected epidemics: Abdullaeva S. Prediction of glycosylated hemoglobin level
Obesity, metabolic syndrome, diabetes and cardiovascular in patients with cardiovascular diseases and type 2 diabetes
diseases - insights from research and prevention strategies. mellitus with respect to anti-diabetic medication. Front
Discover Public Health. 2025;22:106. Endocrinol. 2024;15:1305640.
doi: 10.1186/s12982-025-00496-8 doi: 10.3389/fendo.2024.1305640
26. Smith J, Patel R. Real-world effectiveness of adding newer
22. Global Health and Population Project on Access to Care
for Cardiometabolic Diseases (HPACC). Expanding access generation GLP-1RA to SGLT2i in T2DM patients with
to newer medicines for people with type 2 diabetes in low- CHD. Cardiovasc Diabetol. 2024;23(4):237-250.
income and middle-income countries: A cost-effectiveness doi: 10.1186/s12933-025-02737-1

Volume 9 Issue 3 (2025) 196 doi: 10.36922/EJMO025160133